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Background: Risk factors of anxiety and depression symptoms in patients with chronic obstructive pulmonary
disease (COPD) have been widely researched, but most of them cannot be addressed clinically. The aim of this
study was to investigate whether COPD knowledge level is a risk factor of anxiety and/or depression in COPD
patients in addition to functional capacity and quality of life, and to determine the key topics of COPD knowledge.
Methods: A total of 364 COPD patients from four centers were recruited into this cross-sectional survey. Subjects’
general medical information, assessments of lung function, dyspnea, quality of life, and exercise capacity, and
responses to the Hospital Anxiety and Depression Scale (HAD) and the Bristol COPD Knowledge Questionnaire
(BCKQ) were collected. Partial correlation analysis was performed, and a multivariable model testing risk factors of
anxiety and depression as well as a multivariable model of 13 topics of knowledge derived from BCKQ were
constructed.
Results: Subjects with anxiety or depression were more likely to have less COPD knowledge. Partial correlation
analysis revealed that HAD score was negatively correlated with BCKQ score (rho = −0.153, P = 0.004). BCKQ score
was significant in the multivariable model that tested risk factors of anxiety and depression (P = 0.001, OR = 0.944).
Topics of epidemiology (P < 0.001, OR = 0.653) and infections (P = 0.006, OR = 0.721) were significant in the
multivariable model evaluating 13 topics.
Conclusions: The level of patients’ disease knowledge is a significant risk factor of anxiety and depression in COPD
patients. Epidemiology and infections are key topics of COPD knowledge to target in the Chinese population.
Trial registration: ChiCTR-OCS-12002518
Keywords: COPD, Knowledge, Anxiety, Depression, ComorbiditiesBackground
Anxiety and depression are common psychological dis-
turbances affecting a substantial number of patients with
COPD, with reported prevalence rates of 10–57% for
anxiety and 10–59% for depression [1-4]. Both are sig-
nificantly associated with increased physical disability
and morbidity, decreased health status, and decreased
compliance with medical treatment [4-8].* Correspondence: cqmql@163.com
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unless otherwise stated.Successful psychological or psychiatric interventions
could address anxiety and depression. Exploring the risk
factors of COPD patients with anxiety and/or depression
may be valuable for understanding disease processes and
improving disease prevention.
Some risk factors of anxiety and depression symptoms
in COPD patients have been widely researched, includ-
ing younger age, female gender, current smoker status,
bronchitic phenotype, more advanced disease, cardiovas-
cular comorbidities, and worse functional capacity and
quality of life [1,2,9,10]. However, the overall explanatory
value of these risk factors is weak. New risk factors thatLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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The finding that COPD patients’ anxiety and depression
symptoms improved following pulmonary rehabilitation
provides a valuable clue [11-13].
Patient education, an essential element of pulmonary
rehabilitation, relates to improving COPD patients’ dis-
ease knowledge level [14]. The relief of anxiety and
depression symptoms may be associated with patient
education affecting COPD patients’ disease knowledge
level. We have found that COPD patients with greater
disease knowledge had fewer symptoms of anxiety and
depression in our COPD disease management plan (data
not shown). We hypothesize that COPD patients’ disease
knowledge (including knowledge of epidemiology, aeti-
ology, symptoms, treatment, and disease management of
COPD) is another risk factor related to anxiety and de-
pression symptoms.
In this cross-sectional study, we investigate whether
COPD knowledge level is a risk factor of anxiety and de-
pression symptoms in COPD patients alongside func-
tional capacity and quality of life. We examined the
effect of 13 key topics of COPD knowledge measured
by BCKQ, including (1) epidemiology, (2) aetiology,
(3) symptom, (4) breathlessness, (5) phlegm, (6) infec-
tions, (7) exercise, (8) smoking, (9) vaccination, (10) in-
haled bronchodilators, (11) antibiotics, (12) oral steroids,
and (13) inhaled steroids [15].
Methods
Study design
This study was a cross-sectional survey. It was con-
ducted at four centers in two districts, in accordance
with the Declaration of Helsinki and good clinical prac-
tice guidelines, and was approved by the medical ethics
committee of the second affiliated hospital of Third
Military Medical University. All patients were enrolled
from an outpatient clinic and gave informed consent. The
study was registered in the Chinese Clinical Trial Registry
(www.chictr.org, Registration no: ChiCTR-OCS-12002518).
Participants and measurements
All patients with COPD were consecutively recruited from
four outpatient clinics in Guizhou Province, Chongqing
Municipality, China from September 2012 to June 2013.
All participants were diagnosed with COPD in accordance
with the Global Initiative for Chronic Obstructive Lung
Disease strategy document [16] and confirmed by post-
bronchodilator FEV1/FVC of less than 0.7. Patients with
self-reported comorbidities or COPD exacerbation in the
previous 4 weeks were excluded.
Subjects’ general medical information was collected, in-
cluding age, gender, duration of disease, smoking history,
and highest educational qualification. Lung function tests
were performed according to American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines [17].
In addition, patient-reported outcomes were measured,
including assessment of dyspnea (modified Medical
Research Council Dyspnea scale (mMRC)) [18], psycho-
logical disturbance (HAD scale) [19], quality of life (COPD
Assessment Test (CAT)) [20], and BCKQ [15]. All ques-
tionnaires were completed by subjects independently with
adequate space, a firm writing surface, and a pencil. If the
patient was illiterate or had other complications that
prevented them from completing the questionnaire, the
investigator obtained patient responses by reading each
question out loud verbatim, followed by the corre-
sponding response categories, and entering the patient’s
responses. The investigator did not influence patient
responses. Exercise capacity was assessed using the six-
minute walking distance test (6MWD) carried out accord-
ing to ATS guidelines [21]. Subjects were ordered to walk
as rapidly as possible along a solid and flat corridor for
6 minutes.
Measurement of anxiety and depression
The HAD scale was used to assess anxiety and depression
symptoms in all eligible subjects [19]. It has been used ex-
tensively to screen psychiatric morbidity and has high val-
idity when used as a screening instrument in outpatients
[22]. HAD consists of two 7-item subscales: 7 questions
relate to anxiety (HAD-A) and 7 to depression (HAD-D).
Scores range from 0 to 21 for each subscale, and a score
of 8 or higher on either subscale indicates possible path-
ology. Using this cutoff, HAD shows high sensitivity and
specificity in Chinese patients [23].
Measurement of COPD patients’ disease knowledge level
BCKQ was used to assess eligible COPD patients’ dis-
ease knowledge level. It consists of 13 subscales, each of
which assesses a topic of COPD knowledge: (1) epidemi-
ology, (2) aetiology, (3) symptom, (4) breathlessness, (5)
phlegm, (6) infections, (7) exercise, (8) smoking, (9) vac-
cination, (10) inhaled bronchodilators, (11) antibiotics,
(12) oral steroids, and (13) inhaled steroids. Each topic
contains five questions. Scores range from 0 to 65, with
higher scores suggesting higher disease knowledge level
in COPD patients. BCKQ tests knowledge appropriate
for COPD patients and can be used as a broad cross-
sectional survey instrument [15]. Prior to this study, we
translated, retranslated, and piloted the questionnaire in
a Chinese population [24].
Statistical analysis
Means and standard deviations were computed for vari-
ables including age, pack-year history, duration of COPD,
CAT, mMRC, BCKQ, FEV1, FEV1%, postFEV1, post-
FEV1%, and 6MWT. An independent samples t-test was
used to compare continuous variables between groups
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was used to test categorical variables. Spearman’s correl-
ation coefficients were calculated between HAD total
score and descriptor variables. Partial correlation analysis
was performed to assess the correlation between HAD
and target descriptor variables while controlling for the ef-
fect of other variables. [Additional file 1 provides the de-
tails of this partial correlation analysis]. A combined
analysis of patient-reported outcomes, clinically based de-
scriptors, and lung function test results was performed
using a stepwise logistic regression model. The P-values
necessary for entry into the model and to remain in the
model were both P < 0.1. The same method was used to
assess the 13 topics of the BCKQ.
Results
Subject demographics
A total of 416 subjects were eligible for the study. Fifty
two subjects refused to be included. A total of 364 sub-
jects provided informed consent and entered the study.
Five of these subjects were excluded due to inadequate
completion or loss of data. Therefore, 359 participants
were analyzed. Thirty two participants were female. The
mean age was 65.64 ± 7.60 years. A total of 95 patients
(26.46%) had an HAD-A and/or HAD-D score of ≥ 8.Table 1 Characteristics of subjects stratified by presence of a
Total
Age, mean ± SD 65.64 ± 7.60
Gender, n (male/female) 327/32
Pack-year history, mean ± SD 33.65 ± 18.37
Duration of COPD, years, mean ± SD 6.69 ± 5.32
CAT, mean ± SD 16.42 ± 7.20
mMRC, mean ± SD 1.53 ± 0.85
BCKQ, mean ± SD 30.36 ± 9.59
HAD-A, mean ± SD 3.54 ± 3.74
HAD-D, mean ± SD 4.17 ± 3.76
FEV1, L, mean ± SD 1.11 ± 0.44
FEV1% predict, mean ± SD 42.88 ± 25.56
Post FEV1, L, mean ± SD 1.22 ± 0.47
Post FEV1% predict, mean ± SD 46.77 ± 25.88
6MWD, m, mean ± SD 429.64 ± 115.39
Primary school, n (%) 106 (29.53%)
Junior high school, n (%) 129 (35.93%)
Senior high school, n (%) 59 (16.43%)
Junior college or above, n (%) 55 (15.32%)
Other, n (%) 10 (2.79%)
Abbreviations: CAT COPD Assessment Test, mMRC modified Medical Research Counc
Depressive Scale, HAD-A HAD-anxiety, HAD-D HAD-Depression, FEV1 Forced Expirato
Walking Distance Test; Definition of Anxiety and/or Depression Status: HAS-A ≥8 anThe mean CAT score was 16.42 ± 7.20, the mean mMRC
score was 1.53 ± 0.85, and the mean BCKQ score was
30.36 ± 5.59 - only 46% of the full mark possible. In total,
15.32% had educational qualifications at junior college
level or above. No subjects were receiving treatment for
their anxiety/depression at the time of assessment. More
demographic details are listed in Table 1. Subjects with
anxiety/depression were more likely to be younger, fe-
male, to have worse quality of life, increased dyspnea,
and a lower level of disease knowledge about COPD
(see below).
Correlation of HAD total score with characteristics of
subjects
Spearman correlation analysis revealed significant correla-
tions between HAD score and age, gender, CAT score,
mMRC score, BCKQ score, FEV1, FEV1% predicted, post-
bronchodilator FEV1, post-bronchodilator FEV1% pre-
dicted, and 6MWD.
A partial correlation analysis revealed that higher HAD
total score correlated with female gender (rho = 0.376,
P < 0.001), worse quality of life (CAT score, rho = 0.351,
P < 0.001), increased dyspnea (mMRC, rho = 0.109, P =
0.042), and lower level of COPD knowledge (BCKQ,
rho = −0.153, P = 0.004). No other variables significantlynxiety and/or depression status
Anxiety and/or Depression status P
valueYes (n = 95) No (n = 264)
64.25 ± 7.84 66.14 ± 7.47 0.038
77/18 250/14 <0.001
32.46 ± 20.28 34.08 ± 17.66 0.463
6.77 ± 6.19 6.66 ± 4.98 0.859
20.17 ± 6.50 15.06 ± 6.97 <0.001
1.86 ± 0.86 1.42 ± 0.82 <0.001
26.85 ± 9.16 31.63 ± 9.45 <0.001
7.87 ± 3.69 1.98 ± 2.24 <0.001
8.97 ± 2.69 2.45 ± 2.31 <0.001
1.04 ± 0.41 1.14 ± 0.45 0.062
39.12 ± 14.77 44.23 ± 28.36 0.094
1.16 ± 0.47 1.24 ± 0.46 0.133
43.37 ± 116.19 48.00 ± 28.50 0.135
431.38 ± 124.34 429.01 ± 112.24 0.864
27 (28.42%) 79 (29.92%) 0.783
42 (44.21%) 87 (32.95%) 0.050
14 (14.74%) 45 (31.78%) 0.603
8 (8.42%) 47 (17.80%) 0.029
4 (4.21%) 6 (2.27%) 0.301
il, BCKQ Bristol COPD Knowledge Questionnaire, HAD Hospital Anxiety and
ry Volume in 1 Second, postFEV1 post-bronchodilator FEV1, 6MWD Six-Minute
d/or HAD-D score ≥8.
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history, duration of COPD, FEV1, FEV1% predicted, post-
bronchodilator FEV1, post-bronchodilator FEV1% predicted,
and 6MWD (Table 2).
Risk factors of anxiety and depression
A multivariable model testing risk factors of anxiety
and depression explored factors including age, gender,
CAT, mMRC, BCKQ score, FEV1, FEV1% predicted,
post-bronchodilator FEV1, post-bronchodilator FEV1%
predicted, and 6MWD. Gender (“male” = 0, “female” = 1,
P = 0.001, OR = 3.781), CAT score (P < 0.001, OR = 1.087),
mMRC score (P = 0.050, OR = 1.386) and BCKQ score
(P = 0.001, OR = 0.944) were significant in this model. In
accordance with our hypotheses, level of COPD know-
ledge was a risk factor of anxiety and/or depression symp-
toms in COPD patients alongside functional capacity and
quality of life. However, the overall predictive capability of
the model was very weak (Hosmer and Lemeshow Test,
P = 0.128).
Topics of COPD knowledge and subjects’ anxiety or
depression
The 13 topics of COPD knowledge measured by BCKQ
were assessed. Subjects with anxiety and/or depression
had lower scores in topics (1) epidemiology, (3) symptom,
(4) breathlessness, (5) phlegm, (6) infections, (9) vaccin-
ation, (10) inhaled bronchodilators, and (11) antibiotics.
These topics were used to construct the multivariable








Age −0.122 0.021 −0.036 0.509
Gender† 0.295 0.000 0.376 <0.001
Pack-year history −0.029 0.586 0.051 0.344
Duration of COPD 0.014 0.799 −0.043 0.419
CAT 0.495 0.000 0.351 <0.001
mMRC 0.309 0.000 0.109 0.042
BCKQ −0.217 0.000 −0.153 0.004
FEV1 (L) −0.157 0.003 −0.063 0.243
FEV1% predict −0.174 0.001 0.043 0.425
PostFEV1 (L) −0.145 0.006 0.070 0.194
PostFEV1% predict −0.158 0.003 −0.051 0.341
6MWT −0.112 0.034 0.014 0.789
Abbreviations: CAT COPD Assessment Test, mMRC modified Medical Research
Council, BCKQ Bristol COPD Knowledge Questionnaire, HAD Hospital Anxiety
and Depressive Scale, FEV1 Forced Expiratory Volume in 1 Second, postFEV1
post-bronchodilator FEV1, 6MWD Six-Minute Walking Distance Test.
†Set “male” = 0, “female” = 1.Infections (P = 0.006, OR = 0.721) were significant in
this model. The P value of Hosmer and Lemeshow Test
of this model was 0.919 (Table 3).
Discussion
In this study, 26.46% of COPD patients had anxiety and/
or depression. Subjects with anxiety and/or depression
were significantly more likely to be younger, female, and
to have worse quality of life and increased dyspnea. This
is consistent with previous studies. Worse anxiety and/
or depression symptoms (with higher HAD total scores)
significantly correlated with younger age, female pa-
tients, worse quality of life, increased dyspnea, increased
severity of airway limitation, and lower 6MWD [2,9,10].
The key finding of this study is that the level of pa-
tients’ COPD knowledge was another risk factor of anxiety
and/or depression alongside functional capacity, quality
of life, and gender. A higher HAD score correlated with
lower COPD knowledge (BCKQ, rho = −0.153, P = 0.004).
Previous studies mainly focused on the relationship be-
tween anxiety and/or depression and COPD patients’
clinical features, including patient-reported outcomes,
demographic factors, and objective measures [2,9,10,25].
Most risk factors identified previously could not be ad-
dressed. The ECLIPSE study concluded “subjective mea-
sures, represented by quality of life and symptom, were
stronger determinants of depression than objective mea-
sures, such as lung function and biologic and physiologic
markers” [10]. Level of COPD knowledge, a subjectiveTable 3 Topic score in BCKQ for subjects stratified by
presence of anxiety and/or depression status




Yes (n = 95) No (n = 264)
1 Epidemiology† 2.91 ± 1.06 2.39 ± 1.07 3.10 ± 1.02 <0.001
2 Aetiology 3.56 ± 1.04 3.37 ± 1.07 3.63 ± 1.03 0.098
3 Symptom 2.79 ± 1.01 2.42 ± 0.88 2.92 ± 1.04 0.001
4 Breathlessness 2.92 ± 0.91 2.72 ± 0.96 2.99 ± 0.88 0.047
5 Phlegm 3.23 ± 1.32 2.78 ± 1.42 3.39 ± 1.26 0.003
6 Infections‡ 2.28 ± 1.11 1.83 ± 1.10 2.44 ± 1.09 < 0.006
7 Exercise 2.96 ± 1.22 2.78 ± 1.20 3.03 ± 1.23 0.173
8 Smoking 2.97 ± 0.95 2.80 ± 0.99 3.04 ± 0.93 0.102
9 Vaccination 1.75 ± 1.15 1.49 ± 1.07 1.85 ± 1.16 0.036
10 Inhaled
bronchodilators
1.33 ± 1.06 1.03 ± 1.05 1.44 ± 1.05 0.009
11 Antibiotics 1.48 ± 1.11 1.14 ± 0.97 1.61 ± 1.14 0.003
12 Oral steroids 1.27 ± 1.06 1.28 ± 1.12 1.27 ± 1.04 0.963
13 Inhaled steroids 0.90 ± 0.89 0.83 ± 0.88 0.92 ± 0.90 0.480
Definition of Anxiety and/or Depression Status: HAS-A ≥ 8 and/or HAD-D
score ≥ 8.
†LogisticRegression:P < 0.001, OR = 0.653.
‡LogisticRegression: P = 0.006, OR = 0.721.
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ously ignored and that can be addressed.
However, it is important to point out that the overall
explanatory value of our final four-variable multivariable
regression model was weak. Therefore, although we have
confirmed that level of COPD knowledge was a new risk
factor, none of the factors we measured strongly explained
the presence of anxiety and/or depression in patients with
COPD. Based on these results, we hypothesize that in
COPD patients, anxiety and depression are primarily
driven by the patient’s perception of serious chronic dis-
ease and the mindset of facing this troubled state. Further
research should be conducted to increase knowledge in
this area.
There is controversy over whether the education inter-
ventions in clinical practice were efficacious. For example,
in a randomized trial of exercise, stress management, and
education, investigators did not find the benefit of redu-
cing anxiety in the education group [26], while another
randomized trial of cognitive behavioral therapy and
COPD education reported that both forms of education
were efficacious in reducing anxiety or depressive symp-
toms. A limited number of trials have been performed
[27], all trials used different methods to educate patients,
and none assessed actual change in COPD knowledge.
These defects may have led to different results and points
of view. The content and frequency of education as well
as educational methods all require further study.
To evaluate key topics of COPD knowledge to address
in educational interventions, a further logistic model based
on the 13 topics of BCKQ was constructed. Although sub-
jects with anxiety and/or depression had lower scores in
(1) epidemiology, (3) symptom, (4) breathlessness, (5)
phlegm, (6) infections, (9) vaccination, (10) inhaled bron-
chodilators, and (11) antibiotics, knowledge of topics (1)
epidemiology and (6) infections was found to be a risk fac-
tor for anxiety and/or depression in COPD patients.
The epidemiology topic contains questions such as:
“In COPD, the word ‘chronic’ means that it is severe”.
However, the reason that the epidemiology category was
significant is unknown, we conjecture that this misun-
derstanding of the disease may be involved. A patient
who has misunderstood the meaning of the name COPD
may make incorrect interpretations, such as “I am going
to die”, “I am past all hope”, and “All these treatments
are useless to me”, when he or she is experiencing dys-
pnea. This in turn may lead to a heightened state of
physiological arousal accompanied by further sensations
and misinterpretations.
The category ‘infections’ addresses the relationship be-
tween infections and treatment of COPD exacerbation.
The causes of the significance of this factor were also
unclear. We conjecture that this may be a special topic
in China. Anti-inflammation and anti-infection have thesame meaning for some Chinese patients. They conse-
quently regard COPD as an infectious disease. Because
most Chinese patients have easy access to antibiotics,
this may result in antibiotics abuse and poor outcomes.
COPD patients who understand infection in this way
may have more negative thoughts and emotions than do
patients who can interpret, understand, and treat COPD
correctly. This suggests that patients from different cul-
tural backgrounds may have different results.
We acknowledge the limitations in our study. First,
the overall level of COPD knowledge and education was
low, which accurately reflects the current situation of
COPD patients in West China [24]. In addition, gender
was imbalanced. The number of male patients was nearly
10 times higher than the number of female patients. This
may result from the gender ratio characteristic of COPD.
There was a 3:1 ratio of men to women in the epidemio-
logical investigation, and this is comparable with that of
another multicenter study held in China [28]. The influ-
ence of gender imbalance was limited to the relationship
between the level of COPD knowledge and anxiety/
depression.
Conclusions
A combination of anxiety and depression symptoms is
common in COPD patients. In this study, we found that
the level of COPD patients’ disease knowledge was a risk
factor of anxiety and/or depression alongside functional
capacity and quality of life. Key topics of COPD know-
ledge that could be addressed were (1) epidemiology and
(6) infections. Relevant topics may differ in patients with
different cultural backgrounds. Our study indicates that
the relationship between COPD knowledge level, mental
health, and education strategy is valuable to investigate
in the future.
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